One of the biggest movers on the market today has been the Noxopharm Ltd (ASX: NOX) share price.
The drug development company's shares finished the day 32% higher at 85 cents.
What happened?
This morning Noxopharm released interim data from its first-in-human study of its NOX66 drug being conducted in Georgia.
NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour.
According to the release, the data released by the company shows promising outcomes both in terms of safety and disease control in patients receiving NOX66 in combination with a low dose of carboplatin.
Out of the 11 patients that have been treated for three months with a combination of NOX66 and low-dose carboplatin, only one of the 11 patients showed disease progression over this time. Of the remaining 10 patients, nine showed stable disease and one showed a partial response.
Importantly, NOX66 alone and in combination with low-dose carboplatin was well tolerated and there were no reported adverse events.
While this is a promising start, there is still a long road ahead of Noxopharm and its shareholders.
